Oriental Carbon & Chemicals Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: June 29, 2025, 11:16 am

Competitors of Oriental Carbon & Chemicals Ltd

All Competitor Stocks of Oriental Carbon & Chemicals Ltd

Quarterly Result

Last Updated: May 31, 2025, 8:13 am

Below is a detailed analysis of the quarterly data for Oriental Carbon & Chemicals Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Sales, as of Mar 2025, the value is 27.83 Cr.. The value appears to be declining and may need further review. It has decreased from 29.65 Cr. (Dec 2024) to 27.83 Cr., marking a decrease of 1.82 Cr..
• For Expenses, as of Mar 2025, the value is 25.25 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 25.81 Cr. (Dec 2024) to 25.25 Cr., marking a decrease of 0.56 Cr..
• For Operating Profit, as of Mar 2025, the value is 2.58 Cr.. The value appears to be declining and may need further review. It has decreased from 3.84 Cr. (Dec 2024) to 2.58 Cr., marking a decrease of 1.26 Cr..
• For OPM %, as of Mar 2025, the value is 9.27%. The value appears to be declining and may need further review. It has decreased from 12.95% (Dec 2024) to 9.27%, marking a decrease of 3.68%.
• For Other Income, as of Mar 2025, the value is 0.79 Cr.. The value appears strong and on an upward trend. It has increased from 0.64 Cr. (Dec 2024) to 0.79 Cr., marking an increase of 0.15 Cr..
• For Interest, as of Mar 2025, the value is 0.50 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.12 Cr. (Dec 2024) to 0.50 Cr., marking an increase of 0.38 Cr..
• For Depreciation, as of Mar 2025, the value is 1.05 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1.06 Cr. (Dec 2024) to 1.05 Cr., marking a decrease of 0.01 Cr..
• For Profit before tax, as of Mar 2025, the value is 1.82 Cr.. The value appears to be declining and may need further review. It has decreased from 3.30 Cr. (Dec 2024) to 1.82 Cr., marking a decrease of 1.48 Cr..
• For Tax %, as of Mar 2025, the value is 17.03%. The value appears to be improving (decreasing) as expected. It has decreased from 33.33% (Dec 2024) to 17.03%, marking a decrease of 16.30%.
• For Net Profit, as of Mar 2025, the value is 1.51 Cr.. The value appears to be declining and may need further review. It has decreased from 2.20 Cr. (Dec 2024) to 1.51 Cr., marking a decrease of 0.69 Cr..
• For EPS in Rs, as of Mar 2025, the value is 0.88. The value appears to be declining and may need further review. It has decreased from 1.85 (Dec 2024) to 0.88, marking a decrease of 0.97.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: June 16, 2025, 4:34 pm

Growth

Last Updated: Unknown

Balance Sheet

Last Updated: June 16, 2025, 11:35 am

Below is a detailed analysis of the balance sheet data for Oriental Carbon & Chemicals Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 10.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 10.00 Cr..
• For Reserves, as of Mar 2025, the value is 256.00 Cr.. The value appears to be declining and may need further review. It has decreased from 627.00 Cr. (Mar 2024) to 256.00 Cr., marking a decrease of 371.00 Cr..
• For Borrowings, as of Mar 2025, the value is 3.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 139.00 Cr. (Mar 2024) to 3.00 Cr., marking a decrease of 136.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 57.00 Cr.. The value appears to be improving (decreasing). It has decreased from 120.00 Cr. (Mar 2024) to 57.00 Cr., marking a decrease of 63.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 327.00 Cr.. The value appears to be improving (decreasing). It has decreased from 896.00 Cr. (Mar 2024) to 327.00 Cr., marking a decrease of 569.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 69.00 Cr.. The value appears to be declining and may need further review. It has decreased from 465.00 Cr. (Mar 2024) to 69.00 Cr., marking a decrease of 396.00 Cr..
• For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1.00 Cr. (Mar 2024) to 0.00 Cr., marking a decrease of 1.00 Cr..
• For Investments, as of Mar 2025, the value is 221.00 Cr.. The value appears to be declining and may need further review. It has decreased from 247.00 Cr. (Mar 2024) to 221.00 Cr., marking a decrease of 26.00 Cr..
• For Other Assets, as of Mar 2025, the value is 37.00 Cr.. The value appears to be declining and may need further review. It has decreased from 183.00 Cr. (Mar 2024) to 37.00 Cr., marking a decrease of 146.00 Cr..
• For Total Assets, as of Mar 2025, the value is 327.00 Cr.. The value appears to be declining and may need further review. It has decreased from 896.00 Cr. (Mar 2024) to 327.00 Cr., marking a decrease of 569.00 Cr..

Notably, the Reserves (256.00 Cr.) exceed the Borrowings (3.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Cash Flow

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Mutual Fund Holdings

Key Financial Ratios

After reviewing the key financial ratios for Oriental Carbon & Chemicals Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 10.48. This value is within the healthy range. It has decreased from 46.19 (Mar 24) to 10.48, marking a decrease of 35.71.
• For Diluted EPS (Rs.), as of Mar 25, the value is 10.48. This value is within the healthy range. It has decreased from 46.19 (Mar 24) to 10.48, marking a decrease of 35.71.
• For Cash EPS (Rs.), as of Mar 25, the value is 17.00. This value is within the healthy range. It has decreased from 79.96 (Mar 24) to 17.00, marking a decrease of 62.96.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 266.60. It has decreased from 664.61 (Mar 24) to 266.60, marking a decrease of 398.01.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 266.60. It has decreased from 664.61 (Mar 24) to 266.60, marking a decrease of 398.01.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 108.38. It has decreased from 464.13 (Mar 24) to 108.38, marking a decrease of 355.75.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 15.62. This value is within the healthy range. It has decreased from 108.14 (Mar 24) to 15.62, marking a decrease of 92.52.
• For PBIT / Share (Rs.), as of Mar 25, the value is 11.71. This value is within the healthy range. It has decreased from 77.82 (Mar 24) to 11.71, marking a decrease of 66.11.
• For PBT / Share (Rs.), as of Mar 25, the value is 10.98. This value is within the healthy range. It has decreased from 66.60 (Mar 24) to 10.98, marking a decrease of 55.62.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 13.09. This value is within the healthy range. It has decreased from 49.63 (Mar 24) to 13.09, marking a decrease of 36.54.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 10.48. This value is within the healthy range. It has decreased from 46.19 (Mar 24) to 10.48, marking a decrease of 35.71.
• For PBDIT Margin (%), as of Mar 25, the value is 14.40. This value is within the healthy range. It has decreased from 23.30 (Mar 24) to 14.40, marking a decrease of 8.90.
• For PBIT Margin (%), as of Mar 25, the value is 10.80. This value is within the healthy range. It has decreased from 16.76 (Mar 24) to 10.80, marking a decrease of 5.96.
• For PBT Margin (%), as of Mar 25, the value is 10.13. This value is within the healthy range. It has decreased from 14.34 (Mar 24) to 10.13, marking a decrease of 4.21.
• For Net Profit Margin (%), as of Mar 25, the value is 12.07. This value exceeds the healthy maximum of 10. It has increased from 10.69 (Mar 24) to 12.07, marking an increase of 1.38.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is 9.67. This value is within the healthy range. It has decreased from 9.95 (Mar 24) to 9.67, marking a decrease of 0.28.
• For Return on Networth / Equity (%), as of Mar 25, the value is 3.93. This value is below the healthy minimum of 15. It has decreased from 7.23 (Mar 24) to 3.93, marking a decrease of 3.30.
• For Return on Capital Employeed (%), as of Mar 25, the value is 3.79. This value is below the healthy minimum of 10. It has decreased from 10.20 (Mar 24) to 3.79, marking a decrease of 6.41.
• For Return On Assets (%), as of Mar 25, the value is 3.20. This value is below the healthy minimum of 5. It has decreased from 5.15 (Mar 24) to 3.20, marking a decrease of 1.95.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. It has decreased from 0.07 (Mar 24) to 0.00, marking a decrease of 0.07.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.00. This value is within the healthy range. It has decreased from 0.20 (Mar 24) to 0.00, marking a decrease of 0.20.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 0.17. It has decreased from 0.52 (Mar 24) to 0.17, marking a decrease of 0.35.
• For Current Ratio (X), as of Mar 25, the value is 6.95. This value exceeds the healthy maximum of 3. It has increased from 2.21 (Mar 24) to 6.95, marking an increase of 4.74.
• For Quick Ratio (X), as of Mar 25, the value is 6.18. This value exceeds the healthy maximum of 2. It has increased from 1.69 (Mar 24) to 6.18, marking an increase of 4.49.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 1.19. This value is below the healthy minimum of 4. It has decreased from 2.44 (Mar 24) to 1.19, marking a decrease of 1.25.
• For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 30.71 (Mar 24) to 0.00, marking a decrease of 30.71.
• For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 18.53 (Mar 24) to 0.00, marking a decrease of 18.53.
• For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 69.29 (Mar 24) to 0.00, marking a decrease of 69.29.
• For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 81.47 (Mar 24) to 0.00, marking a decrease of 81.47.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 21.45. This value is within the healthy range. It has increased from 9.64 (Mar 24) to 21.45, marking an increase of 11.81.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 8.73. This value is within the healthy range. It has increased from 5.43 (Mar 24) to 8.73, marking an increase of 3.30.
• For Enterprise Value (Cr.), as of Mar 25, the value is 175.77. It has decreased from 808.28 (Mar 24) to 175.77, marking a decrease of 632.51.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.62. This value is within the healthy range. It has decreased from 1.74 (Mar 24) to 1.62, marking a decrease of 0.12.
• For EV / EBITDA (X), as of Mar 25, the value is 11.27. This value is within the healthy range. It has increased from 7.48 (Mar 24) to 11.27, marking an increase of 3.79.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.45. This value is within the healthy range. It has increased from 1.42 (Mar 24) to 1.45, marking an increase of 0.03.
• For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. It has decreased from 69.28 (Mar 24) to 0.00, marking a decrease of 69.28.
• For Price / BV (X), as of Mar 25, the value is 0.59. This value is below the healthy minimum of 1. It has decreased from 1.03 (Mar 24) to 0.59, marking a decrease of 0.44.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.45. This value is within the healthy range. It has increased from 1.42 (Mar 24) to 1.45, marking an increase of 0.03.
• For EarningsYield, as of Mar 25, the value is 0.06. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.06.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness